Cleveland Clinic Abu Dhabi Partners with BioTwin for Breast Cancer Screening Innovation

BioTwin, a leading Canadian digital health startup and a key player in Abu Dhabi’s Hub71 tech ecosystem, has joined forces with Cleveland Clinic Abu Dhabi, part of the M42 Group, to trial its groundbreaking virtual human twin technology for breast cancer screening. The partnership was announced at Arab Health 2025, underscoring a significant leap forward in medical innovation.

Revolutionizing Early Detection with Virtual Twin Technology

BioTwin’s cutting-edge virtual twin technology utilizes advanced data analytics, machine learning, and biological biomarkers to create dynamic digital replicas of individual patients. These virtual twins serve as personalized health monitors, detecting subtle biological changes that could indicate the early onset of diseases such as breast cancer. By piloting this innovative approach with Cleveland Clinic Abu Dhabi, BioTwin aims to validate its technology and enhance breast cancer screening through highly individualized patient profiling.

Powered by Microsoft for Global Healthcare Innovation

As a participant in the Microsoft Entrepreneurship for Positive Impact initiative, BioTwin benefits from exclusive access to mentorship, training, Azure cloud credits, and strategic partnerships. This pilot program, hosted on Microsoft Azure, demonstrates Microsoft's ongoing commitment to advancing healthcare technology and fostering innovative startups that drive meaningful change in the medical field.

Dr Rafal Iskanderian, Staff Physician, General Surgery, Oncology Institute at Cleveland Clinic Abu Dhabi, said: "Our partnership represents a significant leap forward in breast cancer screening. It aligns with Cleveland Clinic Abu Dhabi's commitment to advancing cancer care in the region by deploying the latest innovations in health-tech, supported by clinical research, global expertise, and state-of-the-art facilities. By leveraging virtual twin technology, we aim to enhance early detection capabilities, potentially saving lives and improving patient outcomes. We are bringing the future right forward here close to home.”

Louis-Philippe Noel, founder and CEO of BioTwin, said: "Our partnership with Cleveland Clinic Abu Dhabi marks a pivotal moment for BioTwin. By combining our virtual twin technology with Cleveland Clinic Abu Dhabi’s expertise, we're poised to revolutionize breast cancer screening and make a real difference in healthcare."

Hub71: Driving Abu Dhabi’s HealthTech Ecosystem

The collaboration highlights Hub71’s role in attracting high-potential tech startups to Abu Dhabi and fostering valuable partnerships with major corporations and government entities. As the MENA region’s fastest-growing startup ecosystem, Hub71 continues to position Abu Dhabi as a thriving hub for HealthTech advancements, reinforcing its leadership in cutting-edge medical innovation.

Dr David Rhew, Vice President and Global Chief Medical Officer, Microsoft Health and Life Sciences, said: “This collaboration exemplifies the power of innovative startups working alongside established healthcare leaders. Through Microsoft Azure, we're helping to accelerate the development and validation of technologies that will lead to better experiences and outcomes in healthcare.”

Ahmad Ali Alwan, CEO of Hub71, said: "We are proud of Hub71 startups and their ability to forge impactful partnerships that drive business growth and scalability. This collaboration underscores Abu Dhabi’s vast potential as a launchpad for startup success, particularly in the healthcare sector, which remains a key economic priority for both the UAE capital and the nation.”

Regulatory Approval and Future Prospects

The Department of Health – Abu Dhabi has previously approved BioTwin’s technology for research, laying the groundwork for this pioneering pilot project. This approval marks a critical step in integrating virtual twin technology into mainstream healthcare, potentially transforming early disease detection and patient monitoring on a global scale.